Get the Stockscreener App
29.70
6.19%
1.73
Pre-market:
28.04
-1.66
-5.59%
Rapport Therapeutics Inc stock is traded at $29.70, with a volume of 819.39K.
It is up +6.19% in the last 24 hours and up +68.46% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$27.97
Open:
$27.97
24h Volume:
819.39K
Relative Volume:
1.21
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.44%
1M Performance:
+68.46%
6M Performance:
+196.11%
1Y Performance:
+45.02%
1-Day Range:
$27.25
$30.72
1-Week Range:
$24.60
$30.72
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
29.70 | 1.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Why Rapport Therapeutics Inc. stock could be next big winnerWeekly Loss Report & Reliable Entry Point Trade Alerts - newser.com
Momentum divergence signals in Rapport Therapeutics Inc. chartForecast Cut & Stock Market Timing Techniques - newser.com
Applying Elliott Wave Theory to Rapport Therapeutics Inc.Inflation Watch & Breakout Confirmation Alerts - newser.com
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success - MSN
Using data filters to optimize entry into Rapport Therapeutics Inc.2025 Winners & Losers & Capital Efficiency Focused Ideas - newser.com
Is Rapport Therapeutics Inc. stock recession proofJuly 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
How Harsha Engineers International Limited Performs During Inflation Historical OverviewVolume Profile Analysis & Free Short-Term Trading Strategies - earlytimes.in
What drives Bitdeer Technologies Group stock priceSmall Cap Stock Opportunities & High Yield Investment Portfolio - Early Times
Rapport Therapeutics Inc. stock momentum explainedJuly 2025 Selloffs & Verified Momentum Stock Ideas - newser.com
Citizens JMP Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $77 - 富途牛牛
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells 40,835 Shares of Stock - MarketBeat
Full technical analysis of Rapport Therapeutics Inc. stockQuarterly Trade Review & Real-Time Market Sentiment Reports - newser.com
Aug Levels: Is Rapport Therapeutics Inc a stock for growth or value investorsPortfolio Update Summary & Real-Time Volume Analysis Alerts - خودرو بانک
Truist Financial Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Insider Sell: Can Coterra Energy Inc expand into new marketsWeekly Volume Report & Real-Time Buy Zone Alerts - khodrobank.com
Nasdaq Moves: Is Rapport Therapeutics Inc undervalued by DCF analysisQuarterly Portfolio Summary & Verified Stock Trade Ideas - khodrobank.com
Is Rapport Therapeutics Inc. stock a value trapMarket Growth Report & Verified Swing Trading Watchlists - خودرو بانک
Market Wrap: Why is Rapport Therapeutics Inc stock going up2025 Winners & Losers & Verified Momentum Stock Alerts - khodrobank.com
Brokerages Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $35.33 - Defense World
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to "Hold" - MarketBeat
Long term hold vs stop loss in Rapport Therapeutics Inc.Market Performance Report & Verified Short-Term Plans - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 6.6%Here's What Happened - MarketBeat
Insider Stock Buying Reaches US$1.77m On Rapport Therapeutics - 富途牛牛
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Rapport Therapeutics Announces Public Offering Agreement - MSN
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up After Insider Buying Activity - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated by Analysts at Truist Financial - Defense World
Why Rapport Therapeutics (RAPP) Is Up 48.9% After Positive Phase 2a Results for RAP-219 in Seizures - Sahm
Truist Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
EPS Watch: What’s the fair value of Rapport Therapeutics Inc. stock2025 Bull vs Bear & Expert Curated Trade Setups - خودرو بانک
Rapport assigned a new Buy at Truist on lead program - Seeking Alpha
Portfolio Shifts: What is Rapport Therapeutics Incs 5 year growth outlook2025 Trading Volume Trends & Weekly Stock Performance Updates - خودرو بانک
Truist Initiates Rapport Therapeutics at Buy With $44 Price Target - MarketScreener
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $44 - 富途牛牛
How to escape a deep drawdown in Rapport Therapeutics Inc.Weekly Trend Recap & Verified Stock Trade Ideas - newser.com
Levels Update: Will Rapport Therapeutics Inc stock go up in YEAR2025 Technical Patterns & Community Supported Trade Ideas - خودرو بانک
Rapport Therapeutics (NASDAQ:RAPP) COO Cheryl Gault Sells 5,000 Shares - MarketBeat
Buyback Watch: Is Rapport Therapeutics Inc a stock for growth or value investorsJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - خودرو بانک
Aug Sentiment: Why is Rapport Therapeutics Inc stock going upMarket Volume Report & Real-Time Volume Triggers - خودرو بانک
MACD Signal: Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Return Report & Weekly Sector Rotation Insights - خودرو بانک
Shorts Report: Is Brown & Brown Inc. stock forming a triangle patternQuarterly Risk Review & Low Risk Entry Point Guides - خودرو بانک
Gains Report: What is Rapport Therapeutics Inc. s 5 year growth outlook2025 Buyback Activity & Fast Momentum Entry Tips - khodrobank.com
Market Trends: What is Rapport Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Stepwise Trade Execution Plans - khodrobank.com
Exit Recap: Does Rapport Therapeutics Inc. meet Warren Buffett’s criteriaJuly 2025 Market Mood & Reliable Intraday Trade Plans - خودرو بانک
Growth Report: Whats the outlook for Rapport Therapeutics Incs sectorJuly 2025 Volume & Fast Entry High Yield Tips - خودرو بانک
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
A Fresh Look at Rapport Therapeutics (RAPP) Valuation After Positive Phase 2a RAP-219 Data Announcement - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):